Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) insider Jeffrey Martini sold 6,250 shares of the stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $166.98, for a total value of $1,043,625.00. Following the completion of the transaction, the insider directly owned 4,266 shares in the company, valued at approximately $712,336.68. This trade represents a 59.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Palvella Therapeutics Stock Down 6.6%
Shares of Palvella Therapeutics stock opened at $153.18 on Friday. Palvella Therapeutics, Inc. has a 12 month low of $72.22 and a 12 month high of $179.95. The business has a fifty day simple moving average of $143.62 and a 200 day simple moving average of $129.63.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.70) EPS for the quarter, beating analysts' consensus estimates of ($1.78) by $0.08. As a group, equities research analysts expect that Palvella Therapeutics, Inc. will post -6.29 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on PVLA shares. Chardan Capital restated a "buy" rating and set a $240.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, October 28th. Raymond James Financial set a $226.00 price target on shares of Palvella Therapeutics in a research report on Friday, October 16th. HC Wainwright started coverage on shares of Palvella Therapeutics in a research note on Friday, November 6th. They set a "strong-buy" rating on the stock. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Finally, Canaccord Genuity Group upped their target price on shares of Palvella Therapeutics from $232.00 to $243.00 and gave the company a "buy" rating in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $213.85.
Check Out Our Latest Stock Analysis on PVLA
Hedge Funds Weigh In On Palvella Therapeutics
Several hedge funds have recently made changes to their positions in the business. Voya Investment Management LLC lifted its position in shares of Palvella Therapeutics by 2.8% in the third quarter. Voya Investment Management LLC now owns 5,878 shares of the company's stock worth $811,000 after purchasing an additional 162 shares in the last quarter. KBC Group NV acquired a new position in Palvella Therapeutics during the first quarter worth $28,000. Northwestern Mutual Wealth Management Co. acquired a new position in Palvella Therapeutics during the second quarter worth $35,000. Sterling Capital Management LLC boosted its holdings in Palvella Therapeutics by 907.7% during the third quarter. Sterling Capital Management LLC now owns 393 shares of the company's stock worth $54,000 after purchasing an additional 354 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Palvella Therapeutics by 31.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,783 shares of the company's stock valued at $248,000 after purchasing an additional 426 shares in the last quarter. 40.11% of the stock is owned by institutional investors.
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company's platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
